Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (585)	4/25/2002 3:15:19 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 1169

<<I therefore wasn't expecting much, and this sounds OK to me. A 20% haircut?>> A trial was designee to show statistical ACR20 significance for P value (each drug arm and combined). "Avetis" explanation (or VRTX is HIDING behind) that broad pts diversity (too many medications, small placebo group, short drug therapy duration, higher MTX or cortico doses...for mild to moderate RA???,...you name it,...) MASKED REAL drug benefit is ONE BIG BS!!!! ALL this after PIIa??? Did they designee trial LIKE THIS, or ALL this is RETROSPECTIVE??? PR data were VERY SCARING, BUT CC did rise my HART BEAT to 250! Miljenko